Literature DB >> 1618602

The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.

R L Bell1, P R Young, D Albert, C Lanni, J B Summers, D W Brooks, P Rubin, G W Carter.   

Abstract

The enzyme 5-lipoxygenase is a key target in the effort to discover drugs which inhibit the pathophysiology associated with the formation of leukotrienes. The research efforts of these laboratories have focused on the discovery of direct enzyme inhibitors of 5-lipoxygenase. In particular, compounds with hydroxamate or N-hydroxyurea functionalities have proven to be potent inhibitors of leukotriene biosynthesis in vitro and more importantly in vivo. One of these compounds, zileuton (N-(1-benzo-[b]-thien-2-ylethyl)-N-hydroxyurea) has been shown recently to be an effective leukotriene inhibitor in man. The critical approaches and breakthroughs in the discovery and development of zileuton are described. In addition, some recent results with zileuton in animals and man are detailed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618602     DOI: 10.1016/0192-0561(92)90182-k

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  28 in total

1.  The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.

Authors:  W M Awni; J H Cavanaugh; R A Braeckman; S Y Chu; K J Patterson; J M Machinist; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.

Authors:  W M Awni; R A Braeckman; G R Granneman; G Witt; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

3.  Antiviral Activity of Nordihydroguaiaretic Acid and Its Derivative Tetra-O-Methyl Nordihydroguaiaretic Acid against West Nile Virus and Zika Virus.

Authors:  Teresa Merino-Ramos; Nereida Jiménez de Oya; Juan-Carlos Saiz; Miguel A Martín-Acebes
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 4.  Lipid peroxidation in cell death.

Authors:  Michael M Gaschler; Brent R Stockwell
Journal:  Biochem Biophys Res Commun       Date:  2017-02-03       Impact factor: 3.575

5.  Effect of zileuton on theophylline pharmacokinetics.

Authors:  G R Granneman; R A Braeckman; C S Locke; J H Cavanaugh; L M Dubé; W M Awni
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

6.  Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.

Authors:  W M Awni; Z Hussein; G R Granneman; K J Patterson; L M Dubé; J H Cavanaugh
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

7.  Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.

Authors:  E Samara; J H Cavanaugh; D Mukherjee; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

8.  The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.

Authors:  S L Wong; W M Awni; J H Cavanaugh; T el-Shourbagy; C S Locke; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

9.  A macrophage cell model for selective metalloproteinase inhibitor design.

Authors:  Faith E Jacobsen; Matthew W Buczynski; Edward A Dennis; Seth M Cohen
Journal:  Chembiochem       Date:  2008-09-01       Impact factor: 3.164

10.  In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.

Authors:  J M Machinist; M J Kukulka; B A Bopp
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.